Compare FHI & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHI | FOLD |
|---|---|---|
| Founded | 1955 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | 1998 | 2006 |
| Metric | FHI | FOLD |
|---|---|---|
| Price | $56.23 | $14.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $54.20 | $27.25 |
| AVG Volume (30 Days) | 705.0K | ★ 2.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 58.82 | 50.00 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $1,102,924,000.00 | N/A |
| Revenue This Year | $9.90 | $20.50 |
| Revenue Next Year | $4.35 | $18.59 |
| P/E Ratio | $43.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $41.55 | $5.66 |
| 52 Week High | $59.05 | $14.50 |
| Indicator | FHI | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 74.18 |
| Support Level | $51.62 | $14.21 |
| Resistance Level | $57.35 | N/A |
| Average True Range (ATR) | 1.45 | 0.02 |
| MACD | 0.21 | -0.00 |
| Stochastic Oscillator | 76.98 | 100.00 |
Federated Hermes provides asset management services for institutional and individual investors. The firm had $902.6 billion in managed assets at the end of 2025, composed of equity (11%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (76%) funds. The firm's cash management operations are expected to generate around 55% of Federated's revenue this year, compared with 27%, 10%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (68% of AUM), institutional investors (25%), and international clients (7%).
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.